A Randomised,Double-Blind, Parallel Group, Placebo-Controlled, Multicentre Study to Evaluate the Safety, Tolerability and Efficacy of Oral GW677954 Capsules 2.5mg, 5mg, 10mg and 20mg a Day for 24 Weeks in Overweight Dyslipidaemic Subjects.
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2017
At a glance
- Drugs Sodelglitazar (Primary)
- Indications Dyslipidaemias; Lipid metabolism disorders
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 12 Dec 2008 New trial record.